Eli Lilly and Co  

(Public, NYSE:LLY)   Watch this stock  
Find more results for LLY
May 22 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range     -
52 week 58.50 - 77.46
Open     -
Vol / Avg. 0.00/3.88M
Mkt cap 82.45B
P/E 36.28
Div/yield 0.50/2.69
EPS 2.05
Shares 1.11B
Beta 0.35
Inst. own 77%
Jul 23, 2015
Q2 2015 Eli Lilly and Co Earnings Release - 9:30AM EDT - Add to calendar
Jul 23, 2015
Q2 2015 Eli Lilly and Co Earnings Call - 9:00AM EDT - Add to calendar
Jun 7, 2015
Eli Lilly and Co Diabetes Business Update - 7:00PM EDT - Add to calendar
May 13, 2015
Eli Lilly and Co at Bank of America Merrill Lynch Health Care Conference
May 4, 2015
Eli Lilly and Co Annual Shareholders Meeting
Apr 23, 2015
Q1 2015 Eli Lilly and Co Earnings Release
Apr 23, 2015
Q1 2015 Eli Lilly and Co Earnings Call
Mar 11, 2015
Eli Lilly and Co at Barclays Healthcare Conference
Mar 3, 2015
Eli Lilly and Co at Cowen Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin 11.40% 12.19%
Operating margin 11.31% 13.56%
EBITD margin - 24.00%
Return on average assets 5.83% 6.60%
Return on average equity 14.02% 14.49%
Employees 39,135 -
CDP Score - 85 B


Lilly Corporate Ctr
United States - Map
+1-317-2762000 (Phone)
+1-317-2763492 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
About Company - Wikipedia


Eli Lilly and Company discovers, develops, manufactures, and sells products in two business segments human pharmaceutical products and animal health products. The Company manufactures and distributes its products through facilities in the United States, Puerto Rico and 11 other countries. Its animal health business, operating through its Elanco division, develops, manufactures, and markets products for both food animals and companion animals. The Company’s products are Humulin, Jentadueto, Axiron, Cymbalta, Strattera, Amyvid, Gemzar, Erbitux, Effient, ReoPro, Posilac, Posilac and Surmax. Its products in Late-Stage are Dulaglutide, Empagliflozin, Ramucirumab, Evacetrapib, Necitumumab, Tanezumab, Edivoxetine, Liprotamase and Ramucirumab.

Officers and directors

John C. Lechleiter Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 61
Bio & Compensation  - Reuters
Derica W. Rice Chief Financial Officer, Executive Vice President - Global Services
Age: 50
Bio & Compensation  - Reuters
Maria A. Crowe President - Manufacturing Operations
Age: 55
Bio & Compensation  - Reuters
Jan M. Lundberg Ph.D. Executive Vice President - Science and Technology, President - Lilly Research Laboratories
Age: 61
Bio & Compensation  - Reuters
Melissa S. Barnes Senior Vice President - Enterprise Risk Management and Chief Ethics and Compliance Officer
Age: 46
Bio & Compensation  - Reuters
Michael J. Harrington Senior Vice President, General Counsel
Age: 52
Bio & Compensation  - Reuters
Stephen F. Fry Senior Vice President - Human Resources and Diversity
Age: 49
Bio & Compensation  - Reuters
Darren J. Carroll Senior Vice President - Corporate Business Development
Bio & Compensation  - Reuters
Enrique A. Conterno Senior Vice President and President - Lilly Diabetes
Age: 48
Bio & Compensation  - Reuters
Susan Mahony Ph.D. Senior Vice President and President - Lilly Oncology
Age: 50
Bio & Compensation  - Reuters